Hidemi Nakagawa
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 185 publications
Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study.
Journal: Dermatology and therapy
Published: May 15, 2025
Author reply to does dermatophytosis of the feet cause acral melanoma?
Journal: The Journal of dermatology
Published: June 21, 2024
High prevalence of dermatophytosis of the feet in acral melanoma of the foot.
Journal: The Journal of dermatology
Published: February 29, 2024
Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.
Journal: Allergology international : official journal of the Japanese Society of Allergology
Published: January 10, 2023
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
Journal: Dermatology and therapy
Published: September 29, 2022
Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Journal: Experimental dermatology
Published: August 05, 2022
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Journal: Dermatology and therapy
Published: April 05, 2022
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
Journal: Dermatology and therapy
Published: October 11, 2021
Effect of anti-interleukin-17 biologics on Krebs von den Lungen-6 level in patients with psoriasis.
Journal: The Journal of dermatology
Published: March 13, 2021
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Journal: Dermatology and therapy
Published: February 16, 2021
Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Journal: Dermatology and therapy
Published: December 21, 2020
Last Updated: 09/26/2026